Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.

Kato K, Ura T, Koizumi W, Iwasa S, Katada C, Azuma M, Ishikura S, Nakao Y, Onuma H, Muro K.

Cancer Sci. 2018 Mar;109(3):785-793. doi: 10.1111/cas.13481. Epub 2018 Feb 15.

2.

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients.

Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, Hechavarría E, González Z, González A, Lugiollo M, Cuevas I, Frómeta C, Mestre BF, Barroso MC, Crombet T, Ferris RL.

Front Pharmacol. 2017 Jun 19;8:382. doi: 10.3389/fphar.2017.00382. eCollection 2017.

3.

Dose-Dependent Induction of an Idiotypic Cascade by Anti-Glycosaminoglycan Monoclonal Antibody in apoE-/- Mice: Association with Atheroprotection.

Sarduy R, Brito V, Castillo A, Soto Y, Griñán T, Marleau S, Vázquez AM.

Front Immunol. 2017 Mar 3;8:232. doi: 10.3389/fimmu.2017.00232. eCollection 2017.

4.

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer.

Takeda M, Okamoto I, Nishimura Y, Nakagawa K.

Lung Cancer (Auckl). 2011 Oct 13;2:59-67. doi: 10.2147/LCTT.S16440. eCollection 2011. Review.

5.

Development and Validation of an Affinity Chromatography-Protein G Method for IgG Quantification.

Paradina Fernández L, Calvo L, Viña L.

Int Sch Res Notices. 2014 Oct 27;2014:487101. doi: 10.1155/2014/487101. eCollection 2014.

6.

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.

Blanco R, Domínguez E, Morales O, Blanco D, Martínez D, Rengifo CE, Viada C, Cedeño M, Rengifo E, Carr A.

Patholog Res Int. 2015;2015:132326. doi: 10.1155/2015/132326. Epub 2015 Nov 8.

7.
8.

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.

Liu H, Yang W, Gao H, Jiang T, Gu B, Dong Q, Xu W, Wu S, Sun X.

Onco Targets Ther. 2015 Feb 25;8:509-18. doi: 10.2147/OTT.S76958. eCollection 2015.

9.

ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.

Alaoui-Jamali MA, Morand GB, da Silva SD.

Front Genet. 2015 Feb 4;6:17. doi: 10.3389/fgene.2015.00017. eCollection 2015. Review.

10.

On the training of young doctors in China.

Wáng YX.

Quant Imaging Med Surg. 2015 Feb;5(1):182-5. doi: 10.3978/j.issn.2223-4292.2014.12.01. No abstract available.

11.

Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody.

Soto Y, Mesa N, Alfonso Y, Pérez A, Batlle F, Griñán T, Pino A, Viera J, Frómeta M, Brito V, Olivera A, Zayas F, Vázquez AM.

MAbs. 2014;6(5):1340-6. doi: 10.4161/mabs.29970. Epub 2014 Oct 30.

12.

Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study.

Babu KG, Prabhash K, Vaid AK, Sirohi B, Diwakar RB, Rao R, Kar M, Malhotra H, Nag S, Goswami C, Raina V, Mohan R.

Onco Targets Ther. 2014 Jun 13;7:1051-60. doi: 10.2147/OTT.S63168. eCollection 2014.

13.

Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.

Tundidor Y, García-Hernández CP, Pupo A, Cabrera Infante Y, Rojas G.

MAbs. 2014 Jul-Aug;6(4):1013-25. doi: 10.4161/mabs.28915. Epub 2014 Apr 23.

14.

Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Solomon MT, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J, Lorenzo-Luaces P, Crombet T.

Cancer Biol Ther. 2014 May;15(5):504-9. doi: 10.4161/cbt.28021. Epub 2014 Feb 12.

15.

Therapeutic approaches to target cancer stem cells.

Diaz A, Leon K.

Cancers (Basel). 2011 Aug 15;3(3):3331-52. doi: 10.3390/cancers3033331.

16.

Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities.

Diaz-Miqueli A, Martinez GS.

Onco Targets Ther. 2013 Jul 24;6:931-42. doi: 10.2147/OTT.S33532. Print 2013.

17.

Stable expression of H1C2 monoclonal antibody in NS0 and CHO cells using pFUSE and UCOE expression system.

Dharshanan S, Chong H, Cheah SH, Zamrod Z.

Cytotechnology. 2014 Aug;66(4):625-33. doi: 10.1007/s10616-013-9615-x. Epub 2013 Jul 24.

18.

A view on EGFR-targeted therapies from the oncogene-addiction perspective.

Perez R, Crombet T, de Leon J, Moreno E.

Front Pharmacol. 2013 Apr 26;4:53. doi: 10.3389/fphar.2013.00053. eCollection 2013.

19.

Prediction and analysis of antibody amyloidogenesis from sequences.

Liaw C, Tung CW, Ho SY.

PLoS One. 2013;8(1):e53235. doi: 10.1371/journal.pone.0053235. Epub 2013 Jan 7.

20.

The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck.

Russell JS, Colevas AD.

Chemother Res Pract. 2012;2012:761518. doi: 10.1155/2012/761518. Epub 2012 Sep 13.

Supplemental Content

Support Center